OncoMatch/Clinical Trials/NCT07227168
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Is NCT07227168 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including STRO-004 and Pembrolizumab for head and neck squamous cell carcinoma hnscc.
Treatment: STRO-004 · Pembrolizumab — This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Esophageal Carcinoma
Gastric Cancer
Colorectal Cancer
Pancreatic Cancer
Cervical Cancer
Endometrial Cancer
Urothelial Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SCRI Denver · Denver, Colorado
- SCRI FCS Sarasota · Sarasota, Florida
- Mass General Cancer Center · Boston, Massachusetts
- NEXT Austin · Austin, Texas
- NEXT San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify